Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

apy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non- Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acut
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
(Date:7/30/2014)... 2014  Packaging Coordinators, Inc. (PCI) is pleased to ... Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered ... United Kingdom and operates regional ... and Tokyo , Japan. Penn Pharma offers ... Commercial dosage form manufacturing, as well as Clinical Packaging, ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... Surgery Foundation Announces Speakers, Moderators and Panelists for 2nd International Symposium on MR-Guided Focused ... CHARLOTTESVILLE, Va. , June ... to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be ... , , , ...
... , SANTA BARBARA, Calif. , June 25 ... Diabetes Research Institute (Sansum) announced today the achievement of a milestone ... Foundation (JDRF). , , ... The world,s most flexible artificial pancreas system platform, currently being used ...
Cached Medicine Technology:Leading Experts to Speak at Focused Ultrasound Symposium 2Leading Experts to Speak at Focused Ultrasound Symposium 3Leading Experts to Speak at Focused Ultrasound Symposium 4Leading Experts to Speak at Focused Ultrasound Symposium 5Leading Experts to Speak at Focused Ultrasound Symposium 6JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 2JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 3JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 4JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 5JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 6
(Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
(Date:7/30/2014)... Bay Aquarium Research Institute (MBARI) have observed a deep-sea ... yearslonger than any other known animal. Throughout this time, ... from predators. This amazing feat represents an evolutionary balancing ... having plenty of time to develop within their eggs, ... little or no food. , Every few months for ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... a garden might help soothe the agitation that commonly strikes ... 17 past studies, British researchers found evidence that watering plants, ... some dementia patients, anxiety. The study authors cautioned that ... subject to study -- and the evidence of a benefit ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
(Date:7/30/2014)... July 30, 2014 “North America Contrast ... data on the North America Contrast Media Injectors market. ... and volume (in units) and average price data (in ... Injectors ,     Interventional Cardiology/Angio Injectors and MRI Injectors ... agent) is a substance used to enhance the contrast ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4
... risks of death are probably higher with aprotinin, a drug ... surgery, compared with lysine analogues, according to a study ... of CMAJ . , On December 3, a ... aprotinin use. The study is being early released in advance ...
... A new report from the Institute of Medicine proposes ... decrease the chances of fatigue-related medical errors and to ... The report does not recommend further reducing residents, ... week set by the Accreditation Council for Graduate Medical ...
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and ... inflammation, announced today that its Board of Directors ... Corporation ("Westaim"), a requisition to call a special ... capital of US$0.80 per share to NUCRYST shareholders. ...
... Health System Builds Resilient, Cost and Energy Efficient Information ... Mass., Dec. 2 EMC Corporation (NYSE: ... today announced that the Daughters of Charity Health System ... California coast, has consolidated storage and servers and implemented ...
... Randomized Comparator Study to Evaluate Efficacy of Commercially ... , WOODCLIFF LAKE, N.J., Dec. 2 ... that it plans to initiate the first clinical ... injection) compared to Vidaza(R) (azacitidine) in adult patients ...
... Dec. 2 Barotz Dental is now one of only ... This is the only laser gum treatment protocol that ... bone tissue around teeth. , ... height of the tissue around teeth, minimizes pain and discomfort ...
Cached Medicine News:Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2
... Oxylab pO2 probes feature response ... seconds for real-time monitoring of ... Oxylab LDFTM, measurements of pO2, ... be obtained from the same ...
Spherical Burr for FR030R, 5 mm....
Tungsten Carbide Burr "HM", 0,7 mm, ISO-No. 007....
"Rosen" burr, 0,7 mm, ISO-No. 007....
Medicine Products: